As a first proxy for phenotype, we analyzed matched whole transcriptome RNAseq data from 332, 96, 135, and 269 tumors having at least 20% tumor cellularity in the SU2C-I, SU2C-WC, HMF and UW mCRPC datasets, respectively, and compared CDK12 intact tumors against those with CDK12BAL for differential genes, pathways, and hallmarks that reflect relevant biological characteristics of mCPRC. The gene discussed is CDK12; the disease is neoplasm.